Last reviewed · How we verify

AMMONIA SOLUTION, STRONG

FDA-approved approved Small molecule Quality 5/100

Strong Ammonia Solution is a marketed product without a specified primary indication, positioning it in a broad but undefined segment of the pharmaceutical market. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition and maintaining current market exclusivity. The lack of detailed revenue and clinical trial data poses a significant risk in assessing the product's market performance and future potential.

At a glance

Generic nameAMMONIA SOLUTION, STRONG
ModalitySmall molecule
PhaseFDA-approved
First approval2007

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: